Search research articles
Contact Us
Filters
Showing results (101-110 of 128) with videos related to
Page
of 13
Sort By:
The Journal of Clinical Investigation
|
February 16, 2026
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model
Shashwat Tripathi, Hinda Najem, Lisa Hurley, et al.
Biorxiv : the Preprint Server for Biology
|
October 31, 2023
<i>Ataxia-telangiectasia mutated</i> ( <i>Atm</i> ) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy
Avani Mangoli, Sophie Wu, Harrison Q Liu, et al.
Nature Communications
|
June 20, 2020
The integrated genomic and epigenomic landscape of brainstem glioma
Lee H Chen, Changcun Pan, Bill H Diplas, et al.
Biorxiv : the Preprint Server for Biology
|
May 3, 2023
Interplay between <i>ATRX</i> and <i>IDH1</i> mutations governs innate immune responses in diffuse gliomas
Seethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Nature Communications
|
January 25, 2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas
Seethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Shiyou Wei, Delong Yin, Shengnan Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2021
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Kirit Singh, Kristen A Batich, Patrick Y Wen, et al.
Nature Cancer
|
June 12, 2025
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial
Eric M Thompson, David M Ashley, Katayoun Ayasoufi, et al.
Nature Communications
|
January 14, 2021
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Matthias Gromeier, Michael C Brown, Gao Zhang, et al.
The Journal of Clinical Investigation
|
June 28, 2024
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma
Hinda Najem, Spencer T Lea, Shashwat Tripathi, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 128) with videos related to
Sort By:
Page
of 13
The Journal of Clinical Investigation
|
February 16, 2026
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma model
Shashwat Tripathi, Hinda Najem, Lisa Hurley, et al.
Biorxiv : the Preprint Server for Biology
|
October 31, 2023
<i>Ataxia-telangiectasia mutated</i> ( <i>Atm</i> ) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy
Avani Mangoli, Sophie Wu, Harrison Q Liu, et al.
Nature Communications
|
June 20, 2020
The integrated genomic and epigenomic landscape of brainstem glioma
Lee H Chen, Changcun Pan, Bill H Diplas, et al.
Biorxiv : the Preprint Server for Biology
|
May 3, 2023
Interplay between <i>ATRX</i> and <i>IDH1</i> mutations governs innate immune responses in diffuse gliomas
Seethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Nature Communications
|
January 25, 2024
Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas
Seethalakshmi Hariharan, Benjamin T Whitfield, Christopher J Pirozzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Shiyou Wei, Delong Yin, Shengnan Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2021
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Kirit Singh, Kristen A Batich, Patrick Y Wen, et al.
Nature Cancer
|
June 12, 2025
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial
Eric M Thompson, David M Ashley, Katayoun Ayasoufi, et al.
Nature Communications
|
January 14, 2021
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Matthias Gromeier, Michael C Brown, Gao Zhang, et al.
The Journal of Clinical Investigation
|
June 28, 2024
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma
Hinda Najem, Spencer T Lea, Shashwat Tripathi, et al.
Page
of 13